

ALLIANCE PARTNERSHIP STRATEGY WITH INDIA, 2016-2021


BOARD MEETING
Ranjana Kumar, Aurelia Nguyen
2-3 December 2015, Geneva




Reach every child
www.gavi.org

Context: The largest Gavi eligible country and contributor to under-immunised children

Number of under-immunised children, 2014



Context: Historical relationship



Context: Importance of India manufacturers and transition ahead

- **Global benefits**

- Market shaping: India-based manufacturers **supplied 60% of vaccine volume to Gavi**; India **demand represents ~30% of total volume**

- **A critical time to act**

- Progress in immunisation but **vaccines for the largest child killers still missing**
- **Positive political environment**
- **All current vaccines and HSS support ending in 2016**
- **India projected to cross GNI eligibility threshold in 2017** (i.e. 2017-2021 transition period)

- **Strategy developed based on PPC-endorsed principles**

Proposed multi-pronged Alliance partnership strategy

1 — Coverage and equity

Increase immunisation coverage and equity in India through targeted support to strengthen the routine immunisation system

2 — New vaccines

Maximise health impact by accelerating adoption of new vaccines in India

3 — Market shaping

Maximise procurement savings and vaccine supply security by sharing information, coordinating tactics and building a long-term strategy that strengthens local public and private sector manufacturers


4 — Sustainability

Ensure that vaccine programmes in India will be sustainable beyond 2021 by supporting the government to plan for the transition and advocating for increased domestic spending on immunisation

1

Coverage and equity: Future support will align with national priority to reach every child

Current HSS support focuses on Government-identified 12 high priority states with low coverage




Future support to build on further analyses to address equity

- Information from upcoming reviews (HSS) and new cMYP
- Synergies with Mission Indradhanush
 - Strengthen routine immunisation
- CCE Optimisation Platform
- Ensure sustainability

2

New vaccines: Catalytic support to accelerate rollouts and unlock domestic resources for scale-up



----- Illustrative uptake curves with Gavi support
 Illustrative delayed rollout without Gavi support



Children missed for immunisation with delayed rollouts

* Routine MR to be preceded by MR campaigns, for which the government is requesting support from Gavi

Market shaping: Strengthened partnership to maximise win-win opportunities

Coordinating strategies and sharing information can optimise:

- **Procurement savings by leveraging increased demand**
- **Short and long term vaccine supply security**
- **Strong local base of vaccine and CCE manufacturers**



*based on average of scenarios
Source: SDF v.12, PPC paper

PPC recommended catalytic support of up to US\$ 500 million; potential to avert half a million future deaths

Indicative vaccine/cash allocation*

	Scope of support	Cost estimates (\$ million)
Vaccines support		
Rota	20% cohort for 3 years	~\$80
Pneumo	20% cohort for 3 years	~\$180
MR (campaign)	2 out of 4 phases	~\$110
HPV	~15% cohort for 1 year	~\$30
Cash support		~\$100
Total (AFC confirmed available resources from Gavi 2016-2020 period)		\$500

Health impact: Additional ~440,000-860,000 future deaths averted

* Financial and vaccine rollout (target population and duration) projections are approximates. Flexibility to be built into operationalising these allocations upon Board approval.

Gavi and Government of India's share of financing for new vaccines

Gavi commitments (for existing support) and projected cost estimates, 2016-2021 (US\$ mil)

	2002	2003	2005	2006	2007	2009	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	Gavi	Govern. of India
Existing vaccine support																			
Injection safety support (INS)																		\$18	>\$180
HepB																		\$26	>\$6
Penta																		\$265	>\$700
IPV													(GPEI)					\$31	>160
Total																		\$340	>\$1,000
Proposed future vaccine support																			
Rota																			
PCV																			
MR																		\$400	~\$240
HPV																			
(Operational support and INS)																			~\$230
Total																		\$400	~\$470



Gavi support




Government of India self-financing

Projected transition period 2017-2021

*


* Cost estimates based on amounts under the current Gavi policy on vaccine introduction grants and campaign operational support, and current vaccine and device prices. Timelines for introductions are tentative. Assumes Government of India sustaining the programmes at the same level at a minimum.

Forecasted support to India versus other large countries, with proposed investments



Post-PPC discussions with the Government of India

- Welcomed strategic partnership and requested enhanced support
- Committed to sustaining Gavi-supported programmes



...India has set its sight on Universal Immunization coverage and aims to launch new vaccines with Gavi support and will reciprocate the sustainability showcased by India in case of Hepatitis B and injection safety in the past

- Discussed joint agreement on action plan with milestones and mechanism for regular updates

THANK YOU

